To determine whether angiotensin II (Ang II) type 2 (AT 2 )-receptor activation associated with cardioprotection induced by Ang II type 1 (AT 1 )receptor blockade during ischaemia-reperfusion (IR) might be reflected in increased AT 2 -receptor, IP 3 -(1,4,5-inositol trisphosphate type 2) receptor and PKC-ε (protein kinase C-ε) proteins and tissue cGMP (cyclic guanosine monophosphate), we measured in vivo left ventricular (LV) systolic and diastolic function and remodelling (echocardiogram/Doppler) and haemodynamics, and ex vivo infarct size, AT 1 -/AT 2receptor, IP 3 -receptor and PKC-ε proteins (immunoblots) and cGMP (enzyme immunoassay) in dogs with reperfused anterior acute myocardial infarction (MI) (90-minute ischaemia, 120-minute reperfusion). Compared with controls (C, n=6) in vivo, candesartan (1 mg/kg i.v. over 30-minute pre-ischaemia, n=6) effectively inhibited the Ang II pressor response (∆%, -14±22% vs. -80±11, p<0.003) and decreased preload (122±35 vs. -2±16%, p<0.01), improved LV systolic ejection fraction (-29±4 vs. -11±5, p<0.03) and diastolic function (E/A ratio, -25±7 vs. 33±13, p<0.004), decreased the extent of LV asynergy (26±20 vs. -31±10% LV, p<0.05) and limited acute LV remodelling (expansion index 19±6 vs. -3±5, p<0.05; thinning ratio -22±2 vs. -4±2, p<0.0003). Ex vivo, candesartan decreased infarct size (55±2 vs. 27±2% risk, p<0.001) and increased infarct zone (IZ) AT 2 -receptor protein by 8-fold (but not AT 1 -receptor protein), IP 3 -receptor protein by 12-fold, PKC-ε protein by 5-fold and cGMP by 40%. Cardioprotective effects of AT 1 -receptor blockade on acute IR injury, LV function, and remodelling may also involve AT 2 -receptor activation and downstream signalling via IP 3 -receptor, PKC-ε and cGMP.
Introduction
Angiotensin II (Ang II) type 1 (AT 1 )-receptor blockade is used for the treatment of hypertension and is undergoing clinical evaluation for the treatment of heart failure and remodelling after myocardial infarction (MI). [1] [2] [3] Reperfusion therapy is now recommended for patients with acute MI. Experimental studies have shown that AT 1 -receptor blockade induces cardioprotection after infarction 4 and during ischaemia-reperfusion (IR). [5] [6] [7] [8] [9] It has been suggested that the cardioprotective effects of AT 1 -receptor blockade during in vivo IR may partly involve Ang II type 2 (AT 2 )-receptor activation, 8, [10] [11] [12] in addition to inhibition of the injurious effects of Ang II. 1 However, the molecular expression of the AT 1 -/AT 2 -receptors, downstream signalling and potential mediators have not been widely studied. We previously showed that acute IR after chronic AT 1 -receptor blockade (using pretreatment) is associated with AT 2 -receptor activation, increased nitric oxide (NO) release, reflected by increased cyclic guanosine 3', 5' monophosphate (cGMP), protein kinase C-ε (PKC-ε) activation and 1,4,5-inositol trisphosphate type 2 (IP 3 )receptor expression. 13 In this study, 14 we tested the hypothesis that AT 2 -receptor activation, during cardioprotection induced by acute AT 1 -receptor blockade during in vivo IR, is associated with increased AT 2 -receptor protein as well as IP 3receptor and PKC-ε proteins and cGMP.
Methods

Experimental preparation
All experiments conformed with institutional guidelines of the Animal Welfare Committee (AWC) and the 'Position of the American Heart Association Research Animal Use' adopted by the AHA in November 1984. We used a modified dog model as we have described previously. 4, 13 Briefly, healthy mongrel dogs (weight, 16 to 22 kg) underwent a left thoracotomy and neck incision under general anaesthesia (sodium pentobarbital, 30 mg/kg intravenously). Catheters were inserted in the external jugular vein, internal carotid artery and left atrium for haemodynamics. A silk snare was placed around the left anterior descending coronary artery, just below the second diagonal branch, for occlusion and subsequent reperfusion.
Acute ischaemia-reperfusion protocol
The animals (n=18) were randomised to four groups: sham, no IR, saline, n=3; sham, no IR, candesartan (gift from AstraZeneca, Canada), 30minute intravenous infusions (1 mg/kg in 40 mL saline), n=3; IR and candesartan over 30-minute pre-ischaemia, n=6; IR and saline vehicle (controls), n=6. AT 1 -receptor blockade was confirmed by inhibition of the pressor response to Ang II (0.25 µg/kg intravenously) given before (baseline) and after the infusions. Ischaemia was produced by tightening the snare for 90 minutes and reperfusion by releasing the snare for 120 minutes. Serial electrocardiograms (ECGs), left atrial and arterial pressures, two-dimensional echocardiograms and transmitral Doppler (Hewlett-Packard, Sono 1000; 3.5 or 5 MHz transducer) were recorded at four intervals: (i) baseline before infusions; ii) at the end of the infusion and just before coronary occlusion; (iii) after 90 minutes of coronary occlusion, just before reperfusion; and (iv) at 120 minutes after reperfusion.
Infarct size
After final recordings, diastolic arrest was produced with 1M KCl. Hearts were removed, rinsed in saline, weighed and five transverse sections made parallel to the atrioventricular groove. Myocardial samples (~500 mg) were taken from the infarct zone (IZ) and the non-infarct zone (NIZ), weighed and stored in liquid nitrogen for molecular assays. The transverse sections were then incubated in triphenyl tetrazolium chloride (TTC 1% in 0.09 M phosphate-buffered saline [PBS], pH 7.4; Fisher Scientific Co., Fairlawn, NJ) for 30 minutes at 37 o C to delineate infarct tissue. Risk regions were marked at boundaries between vascular beds. Outlines of LV rings, risk regions and infarct areas were made on plastic overlays. Infarct size was measured by computerised planimetry (Hewlett-Packard Vectra 486/33T computer; Summagraphics-Summasketch III).
Off-line analysis of echocardiograms
As described previously, 4, 13, 14 coded echocardiograms were analysed double-blind (on playback of video tapes or optical disks) for in vivo LV systolic functional and remodelling parameters (LV asynergy; global ejection fraction; thinning ratio, expansion index and global shape index). Transmitral Doppler records were analysed 13, 14 for early (E) and late (A) filling velocities, the peak E/A velocity ratio, and the deceleration time (DT).
Biochemical analyses
As described previously, 13,14 AT 1 -, AT 2 -, and IP 3receptors and PKCε proteins were assessed by Western immunoblots. Briefly, aliquots of LV tissue (10 mg) were homogenised (2% SDS [sodium dodecyl sulfate], 100 mmol/L dithiothreitol, 60 mM Tris, pH 6.8) and subjected to electrophoresis on a 9% polyacrylamide gel (PAGE) in SDS, followed by electrotransfer to nitrocellulose. The nitrocellulose membranes were blocked with PBS supplemented with 5% wt/vol skimmed milk powder and 0.05% vol/vol of Tween 20. To determine AT 1 -receptor protein, the membranes were incubated with rabbit anti-human AT 1 -receptor antibody (Santa Cruz, CA, USA) (dilution of 1:2000). The membranes were washed with PBS-Tween 20 (0.05%,TPBS), incubated with goat antirabbit IgG antibody (dilution 1:4000) conjugated to peroxidase and visualised using chemiluminescence detection (ECL Western blot kit,Amersham, Buckinghamshire, UK). Band intensities were quantified by scanning densitometry. To determine AT 2 -receptor protein, the same procedure as that for AT 1 -receptor protein was used, except that incubation with goat anti-human AT 2 -receptor antibody (Santa Cruz, CA, USA) (dilution 1:500) was used, followed by incubation with donkey anti-goat IgG (BioCan Scientific, Mississauga). To determine detection of IP 3 -receptor and PKCε proteins, the same procedure as for AT 1 -receptor was used, except that incubation with goat anti-human nPKCε and IP 3 type 2 antibodies (Santa Cruz, CA, USA) (dilution 1:100) were used, followed by incubation with donkey anti-goat IgG. Consistent gel transfer efficiency was confirmed by reversible Ponceau staining and gel retention by Coomassie blue staining. 13, 14 To determine LV cGMP content (fmol/mg wet weight) enzyme immunoassay (Amersham, Buckinghamshire, UK) was used. 13, 14 Statistics Data were analysed in blinded fashion using analysis of variance (ANOVA) for group comparisons, repeated measures ANOVA for comparing serial data within groups, linear regression analyses by the least square fit method and comparison of r-values and slopes by ANOVA. Data are shown as mean±SEM. Statistical significance was set at p<0.05.
Results
Effect of AT 1 -receptor blockade on in vivo haemodynamics, pressor response and ischaemic injury
There were no changes in sham animals. Compared with the control group, candesartan produced marked inhibition of the Ang II pressor response before occlusion, decreased preload after IR and decreased ischaemic injury on ECG (leads I, II, AV L ) ( Figure 1 ).
Effect of AT 1 -receptor blockade on in vivo LV remodelling and function
There were no changes in sham animals. Compared with controls, by echocardiography, candesartan preserved infarct wall thickness and increased the IZ/NIZ thickness ratio, reduced the IZ segment length and IZ/NIZ segment length ratio (expansion index), decreased end-diastolic and end-systolic volumes, increased LV ejection fractions, reduced the total endocardial surface area of LV asynergy at end-diastole and decreased the global shape index (ratio of short-axis to longaxis lengths) ( Figure 2 ). On transmitral Doppler, candesartan decreased the peak A velocity and increased the DT and E/A ratio, indicating improved diastolic relaxation (Figure 3) . Peak E velocity did not change.
Effect of AT 1 -receptor blockade on infarct size
No infarction was detected in sham hearts. Compared with controls, candesartan decreased infarct size both as percentage of risk region and as percentage of LV (Figure 4 ).
Effect of AT 1 -receptor blockade on AT 1 -and AT 2 -receptor proteins
There was no change in AT 1 -receptor protein for S163
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March 2001 Volume 2 Supplement 1 S164 the IZ and NIZ of hearts from sham, control or candesartan groups ( Figure 5 ). In contrast, there was a marked increase in AT 2 -receptor protein in the IZ of candesartan-treated hearts ( Figure 5 ).
Effect of AT 1 -receptor blockade on IP 3receptor and PKCε proteins
There was a marked increase in IP 3 -receptor and PKCε proteins in the IZ of candesartan-treated hearts ( Figure 6 ).
Effect of AT 1 -receptor blockade on cGMP content
There was an increase in cGMP content in infarcted hearts and this increase was most marked in the IZ of candesartan-treated hearts (Figure 7 ).
Discussion
The results of this study indicate that the cardioprotective effects of acute AT 1 -receptor blockade on IR injury are associated with regional increases in AT 2 -(not AT 1 )-receptor, IP 3 -receptor and PKCε proteins in the IZ, and a greater increase in cGMP content in the IZ. These results suggest that cardioprotection induced by acute AT 1 -receptor blockade during IR is associated with AT 2 -receptor activation and possibly downstream signalling via IP 3 -receptor and PKCε proteins.
Potential mechanisms
The precise mechanisms by which three specific proteins and cGMP contribute in the cardioprotective response of acute AT 1 -receptor blockade during IR remains to be defined. Evidence for cardioprotection in our study included i) decreased preload, ischaemic injury and infarct size; ii) improved LV systolic and diastolic function, and iii) attenuation of LV remodelling. Evidence of AT 1 -receptor blockade was provided by inhibition of Ang II pressor responses. Although we did not measure flow, this may have contributed, since the dog heart has a rich collateral supply and acute coronary occlusion in this model results in low-flow ischaemia. The fact that the decrease in infarct size can be abolished by AT 2 -receptor, bradykinin (BK) and cyclooxygenase antagonists, 8 supports the role of AT 2 -receptor activation, BK and prostaglandins in cardioprotection. We did not study the effect of AT 2 -receptor blockade in this model.
Our finding of a selective increase in AT 2 -receptor protein in the IZ strongly suggests that it is linked to IR and that AT 2 -receptor activation participates in the cardioprotective effect. Activation of the AT 2 -receptor was shown to increase the release of BK and NO in canine coronary arteries. 15 Stimulation of the AT 2 -receptor was shown to increase aortic cGMP by increasing BK and NO in stroke-prone spontaneously hypertensive rats. 12 In the present study, we showed that increased AT 2 -receptor protein is associated with an increase in cGMP (an index of NO formation in LV tissue). Taken together, the findings suggest that, during AT 1 -receptor blockade, Ang II may stimulate AT 2 -receptors, and thereby stimulate the production of BK and NO, increase cGMP and contribute to cardioprotection.
In our study, the lack of change in AT 1 -receptor protein in the IZ might reflect the net effect of the AT 1 -receptor upregulation (secondary to AT 1receptor antagonism) and downregulation induced by increased NO (secondary to AT 2 -receptor activation). The concomitant increases in AT 2receptor, IP 3 -receptor and PKCε proteins in the IZ and the greater increase in cGMP in the IZ suggest that they are all associated with IR and participate in cardioprotection. Further studies are needed using AT 2 -receptor blockade, PKC inhibition or NO synthase inhibition.
Implication
Our results are pertinent for the hypertensive patient who develops an acute coronary syndrome while taking an AT 1 -receptor blocker.
Conclusions
This study shows that the cardioprotective effects of acute AT 1 -receptor blockade on ischaemic injury, March 2001 Volume 2 Supplement 1 S166 PAPER infarct size, LV systolic and diastolic dysfunction, and LV remodelling with acute IR are associated with increases in AT 2 -receptor,IP 3 -receptor and PKCε proteins in the IZ, as well as a greater increase in cGMP in the IZ. These results suggest that AT 2 -receptor activation and possibly downstream signalling via IP 3receptor, PKCε and cGMP might play a role in the cardioprotective effect of AT 1 -receptor blockade.
